Zyllt and acetylsalicylic acid in coronary atherosclerosis patients after coronary artery bypass graft intervention. Main results of the ZEUS Study: medication effectiveness, acetylsalicylic acid resistance mechanisms, short and long-term clinical outcomes

Aim. To study the effectiveness and safety of clopidogrel and acetylsalicylic acid (ASA) in coronary atherosclerosis (CA) patients after coronary artery bypass graft surgery (CABG). To investigate intracellular metabolic activity of platelets and its association with platelet aggregation.

Material and methods. In total, 94 45-72-year-old men with coronary heart disease (CHD) and initially increased platelet aggregation (PLA) were randomised into two groups, receiving clopidogrel (75 mg/d; n=44) or ASA (75–100 mg/d; n=50). The patients not responding to the two-week therapy were regarded as therapy-resistant.

Results. In CHD patients after CABG, ASA resistance developed in 24%. In contrast to ASA, clopidogrel action mechanisms are based on the inhibition of platelet energy metabolism, and increased substrate flow towards nonprotein synthesis in red blood cells. These features could explain the development of laboratory-diagnosed resistance for ASA, but not clopidogrel. End-point analysis demonstrated that clopidogrel is more effective than ASA in the prevention of acute coronary syndrome, de novo angina, and cardiovascular death during the two-year follow-up of the post-CABG patients.

Conclusion. Clopidogrel therapy was not associated with laboratory-diagnosed resistance, and was more effective in terms of acute coronary event prevention than ASA.

1. Антитромботическая терапия у больных со стабильными проявлениями атеротромбоза. Российские рекомендации. Кардиоваск тер проф 2009; 6 (Приложение 6): 5-20.

2. Eagle KA, Guyton RA, Davidoff R, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines Committee to Update the, American Society for Thoracic Surgery, Society of Thoracic Surgeons. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). JACC 2004; 44(5): e213-e310.

3. Mangano DT. Aspirin and mortality from coronary bypass. N Engl J Med 2002; 347(17): 1309-17.

4. Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. JACC 2005; 43(6): 1112-5.

5. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110(19): 489-93.

6. Sanderson S, Baglin T, Kinmonth AL. Narrative revive: aspirin resistance and its clinical implications. Ann Int Med 2005; 142: 370-80.

7. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27(6): 647-54.

8. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. JACC 2003; 41(6): 961-5.

9. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 2007; 106: 1893-900.

10. Гринштейн Ю.И., Савченко Е.А., Филоненко И.В. и др. Зилт у пациентов с атеросклерозом коронарных артерий после коронарного шунтирования. Предварительные результаты открытого, рандомизированного сравнительного исследования ЗЕВС. Кардиоваск тер профил 2008; 6: 43-9.

11. Баркаган З.С. Диагностика и контролируемая терапия нарушений гемостаза. Москва 2001; 285 с.

12. Момот А.П. Патология гемостаза. Принципы и алгоритмы клинико-лабораторной диагностики. СПб.: «Форма Т» 2006; 208 с.

13. Савченко А.А. Биолюминесцентное определение активности НАД и НАДФ-зависимых глутаматдегидрогеназ лимфоцитов. Лаб дело 1991; 11: 22-5.

14. Савченко А.А., Сунцова Л.Н. Высокочувствительное определение активности дегидрогеназ в лимфоцитах периферической крови биолюминесцентным методом. Лаб дело 2006; 11: 23-5.

15. Березов Т.Т., Коровкин Б.Ф. Биологическая химия. М.: «Наука» 1998; 704 с.

16. Досон Р., Элиот Д., Элиот И., Джонс K. Справочник биохимика. М.: «Мир» 1991; 554 с.

17. Nazaret C, Heiske M, Thurley K, Mazat JP. Mitochondrial energetic metabolism: a simplified model of TCA cycle with ATP production. J Theor Biol 2009; 258(3): 455-64.

18. Saheki T, Iijima M, Li MX, et al. Citrin/mitochondrial glycerol3-phosphate dehydrogenase double knock-out mice recapitulate features of human citrin deficiency. J Biol Chem 2007; 282(34): 25041-52.